Strides Pharma Science’s arm receives USFDA’s approval for Gabapentin Tablets

05 Mar 2024 Evaluate

Strides Pharma Science’s step?down wholly owned subsidiary -- Strides Pharma Global, Singapore, has received approval for Gabapentin Tablets USP, 600 mg and 800 mg, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty LLC.  

Gabapentin tablets has a market size of around $140 million as per IMS. This approval further strengthens the Company's presence in the Gabapentin portfolio, complementing the existing approval of Gabapentin capsules, which has a market size of $208 million. The Gabapentin tablets will be manufactured at the company’s facility in Puducherry.

The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 235+ ANDAs have been approved. The company has set a target to launch around 60 new products over three years in the US.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.


Strides Pharma Scien Share Price

684.30 -15.00 (-2.15%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.